Alcon spends up to $200m to co-develop customisable cataract lenses with RxSight

The companies will combine their expertise to develop a ‘tuneable’ presbyopia-correcting intraocular lens (PCIOL) for cataract patients. The companies will combine their expertise to develop a ‘tuneable’ presbyopia-correcting intraocular lens (PCIOL) for cataract patients. Research indicates that cataracts are the leading cause of blindness and visual impairment globally, affecting over 90 million people. Credit: Toa55 / Shutterstock.com Alcon and RxSight are pairing up to jointly develop a new adjustable lens to give surgeons the ability to fine-tune visual outcomes for cataract patients following surgery. The eyecare specialists are set to create a presbyopia-correcting intraocular lens (PCIOL), a premium vision implant…

Source: Medical Device Network